Ramipril

Generic Name: Ramipril

Brand Names: Altace, Altace HCT

Drug Type: Small Molecule

Chemical Formula: C_₂₃H_₃₂N_₂O_₅

CAS Number: 87333-19-5

Unique Ingredient Identifier: L35JN3I7SJ

Background: Ramipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure...

Indication: For the management of mild to severe hypertension. May be used to reduce cardiovascular mortality following myocardial infarction in hemodynamically stable individuals who develop clinical signs of congestive heart failure within a few days following myocardial infarction. To reduce the rate of death, myocardial infarction and stroke in individuals at high ...

Associated Conditions: Cardiovascular Events, Diabetic Nephropathy, Heart Failure, Hearth Failure With Reduced Ejection Fraction (HFrEF), Hypertension, Myocardial Infarction, Nondiabetic proteinuric chronic kidney disease, Stroke, High risk cardiovascular event

Associated Therapies: -

Clinical Trials

Colchicine Versus Beta-blockers, Angiotensin-converting Enzyme Inhibitors, and Statins for Prevention of Chemotherapy-Induced Cardiomyopathy

Phase 1

Not yet recruiting

Conditions: Chemotherapy Induced Systolic Dysfunction

Interventions: Drug: Placebo
Drug: Carvedilol
Drug: Colchicine
Drug: Ramipril
Drug: Rosuvastatin

First Posted Date: 2024-03-12

Last Posted Date: 2024-03-12

Lead Sponsor: Arab Contractors Medical Centre

Target Recruit Count: 150

Registration Number: NCT06304896

Locations: 🇪🇬
Arab Contractors Medical Centre, Cairo, Egypt

The Effect of Sacubitril/valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients with Ischemic Heart Failure with Mid-range Ejection Fraction

Phase 3

Recruiting

Conditions: Heart Failure with Moderately Reduced Ejection Fraction

Interventions: Drug: Sacubitril / Valsartan
Drug: Ramipril

First Posted Date: 2022-08-19

Last Posted Date: 2024-10-31

Lead Sponsor: John Paul II Hospital, Krakow

Target Recruit Count: 666

Registration Number: NCT05508035

Locations: 🇵🇱
Krakowski Szpital Specjalistyczny im. św. Jana Pawła II, Kraków, Małopolskie, Poland

Safety and Efficacy of ACEI in Alport Syndrome Patients With COL4A3/COL4A4/COL4A5 Variants

Not Applicable

Not yet recruiting

Conditions: Alport Syndrome

Interventions: Drug: Ramipril

First Posted Date: 2021-11-24

Last Posted Date: 2021-11-24

Lead Sponsor: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Target Recruit Count: 510

Registration Number: NCT05133050

Locations: 🇨🇳
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

Ramipril in Pediatric Patients on Hemodialysis

Phase 2

Completed

Conditions: Hemodialysis

Interventions: Drug: Ramipril
Drug: placebo

First Posted Date: 2020-10-09

Last Posted Date: 2020-10-14

Lead Sponsor: Ain Shams University

Target Recruit Count: 135

Registration Number: NCT04582097

Locations: 🇪🇬
Ain Shams University Hospital, Cairo, Egypt

African American Study of Kidney Disease and Hypertension

Phase 3

Completed

Conditions: Hypertensive Nephrosclerosis
Chronic Renal Insufficiency

Interventions: Other: MAP goal less than or equal to 92 mm Hg
Other: MAP goal 102-107 mm Hg
Drug: Ramipril
Drug: Amlodipine
Drug: Metoprolol

First Posted Date: 2020-04-27

Last Posted Date: 2020-04-27

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 1094

Registration Number: NCT04364139

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

Completed

Conditions: Hypertension

Interventions: Drug: Ramipril
Drug: Telmisartan

First Posted Date: 2020-04-21

Last Posted Date: 2023-07-27

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 63744

Registration Number: NCT04354350

Locations: 🇺🇸
Brigham And Women's Hospital, Boston, Massachusetts, United States

Ramipril, Endothelial Function and Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: Ramipril

First Posted Date: 2019-06-10

Last Posted Date: 2019-06-10

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 37

Registration Number: NCT03979976

Locations: 🇧🇷
Federal University of São Paulo, São Paulo, Brazil

Effect of Some Drugs on Liver Fibrosis

Phase 3

Recruiting

Conditions: Liver Fibroses

Interventions: Drug: Candesartan
Drug: Ramipril

First Posted Date: 2018-12-10

Last Posted Date: 2018-12-10

Lead Sponsor: Sherief Abd-Elsalam

Target Recruit Count: 45

Registration Number: NCT03770936

Locations: 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt

Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction

Phase 2

Completed

Conditions: Myocardial Infarction

Interventions: Drug: Firibastat
Drug: Ramipril

First Posted Date: 2018-10-23

Last Posted Date: 2023-02-27

Lead Sponsor: Quantum Genomics SA

Target Recruit Count: 295

Registration Number: NCT03715998

Locations: 🇭🇺
Central Hospital of Hungarian Army, Budapest, Hungary
🇵🇱
Krakowski Szpital Specjalistyczny im. Jana Pawła II, Kraków, Poland
🇸🇰
NUSCH Bratislava Dpt. of Acute Cardiology, Bratislava, Slovakia

and more 4 locations

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Phase 2

Active, not recruiting

Conditions: Cognitive Decline
Glioblastoma
Radiotherapy; Complications
Chemoradiation

Interventions: Drug: Ramipril

First Posted Date: 2018-03-23

Last Posted Date: 2024-11-25

Lead Sponsor: Wake Forest University Health Sciences

Target Recruit Count: 75

Registration Number: NCT03475186

Locations: 🇺🇸
John H Stroger Jr Hospital of Cook County, Chicago, Illinois, United States
🇺🇸
Swedish Medical Center-Ballard Campus, Seattle, Washington, United States
🇺🇸
Swedish Medical Center-Cherry Hill, Seattle, Washington, United States

and more 417 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy